BidaskClub lowered shares of BioTime, Inc. (NYSEMKT:BTX) from a sell rating to a strong sell rating in a research report report published on Wednesday morning.

A number of other research firms also recently weighed in on BTX. ValuEngine upgraded BioTime from a sell rating to a hold rating in a research note on Friday, June 23rd. Zacks Investment Research upgraded BioTime from a hold rating to a buy rating and set a $3.50 price target for the company in a research note on Tuesday, July 18th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the company. BioTime has a consensus rating of Hold and an average target price of $5.33.

BioTime (NYSEMKT BTX) traded up 0.74% during midday trading on Wednesday, reaching $2.71. The company had a trading volume of 221,167 shares. The company has a market cap of $313.83 million, a PE ratio of 4.55 and a beta of 1.37. The company’s 50-day moving average is $2.81 and its 200 day moving average is $2.99. BioTime has a 52-week low of $2.47 and a 52-week high of $3.96.

ILLEGAL ACTIVITY WARNING: This story was published by Watch List News and is the property of of Watch List News. If you are accessing this story on another site, it was copied illegally and republished in violation of international trademark and copyright law. The original version of this story can be viewed at https://www.watchlistnews.com/biotime-inc-btx-lowered-to-strong-sell-at-bidaskclub/1641562.html.

In related news, Director Broadwood Partners, L.P. acquired 10,000 shares of the company’s stock in a transaction on Tuesday, August 22nd. The stock was purchased at an average cost of $2.60 per share, with a total value of $26,000.00. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Over the last three months, insiders have purchased 2,866,203 shares of company stock valued at $7,481,218.

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Nationwide Fund Advisors raised its holdings in BioTime by 2.2% in the 1st quarter. Nationwide Fund Advisors now owns 44,578 shares of the biotechnology company’s stock valued at $154,000 after acquiring an additional 939 shares in the last quarter. Family Management Corp raised its holdings in BioTime by 1.4% in the 2nd quarter. Family Management Corp now owns 140,371 shares of the biotechnology company’s stock valued at $442,000 after acquiring an additional 2,000 shares in the last quarter. American International Group Inc. raised its holdings in BioTime by 8.3% in the 1st quarter. American International Group Inc. now owns 39,794 shares of the biotechnology company’s stock valued at $137,000 after acquiring an additional 3,036 shares in the last quarter. Metropolitan Life Insurance Co. NY raised its holdings in BioTime by 14.7% in the 1st quarter. Metropolitan Life Insurance Co. NY now owns 57,694 shares of the biotechnology company’s stock valued at $199,000 after acquiring an additional 7,411 shares in the last quarter. Finally, Voya Investment Management LLC raised its holdings in BioTime by 38.3% in the 2nd quarter. Voya Investment Management LLC now owns 32,496 shares of the biotechnology company’s stock valued at $102,000 after acquiring an additional 8,996 shares in the last quarter.

About BioTime

BioTime, Inc is a clinical-stage biotechnology company focused on developing and commercializing products addressing degenerative diseases. Its clinical programs are based on two platform technologies: pluripotent stem cells and cell/drug delivery platform technologies. The foundation of its cell delivery platform is its HyStem cell and drug delivery matrix technology.

Receive News & Ratings for BioTime Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTime Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.